Clinical Trials Logo

Rhinitis, Allergic clinical trials

View clinical trials related to Rhinitis, Allergic.

Filter by:

NCT ID: NCT05880134 Completed - Neurectomy Clinical Trials

Graft Reinforcement for Posterior Nasal Nerve Neurectomy in Allergic Rhinitis Surgeries

Start date: March 12, 2022
Phase: N/A
Study type: Interventional

Rhinitis is defined clinically as having two or more symptoms of anterior or posterior rhinorrhea, sneezing, nasal blockage and/or itching of the nose during two or more consecutive days for more than 1 h on most days. Allergic rhinitis is diagnosed when these symptoms are caused by allergen exposure leading to an IgE mediated reaction. The inflammatory mediators produced because of this IgE mediated reaction causes the classical symptoms of allergic rhinitis. Nerve irritation causes sneezing and itching, the loss of mucosal integrity causes rhinorrhea, and the vascular engorgement leads to nasal blockage. Based on the nasal symptoms the prevalence of allergic rhinitis in the Indian population is 20-30%. Allergic rhinitis significantly affects the quality of life, it contributes to missed or unproductive time at school or work, disturbed sleep pattern and daytime somnolence. The most popular and widely accepted treatment strategy for allergic rhinitis is pharmacotherapy, this includes antihistamines, leukotriene receptor antagonist and intranasal corticosteroids. These medical modalities are symptomatically effective in mild cases, with temporary relief and addressable adverse effects. Prolonged treatment with allergy immunotherapy causes a sustainable financial burden while remaining inaccessible at smaller towns. Rhinorrhea is a frequent symptom reported amongst patients with allergic and vasomotor rhinitis. Most of these patients usually respond well to medical treatment. Indications for surgical treatment are warranted only when medical treatment fails, or a patient wants a permanent solution. In 1961, Golding-Wood first described vidian neurectomy for the treatment of allergic and vasomotor rhinitis. There was a high incidence of post-operative complications, such as disturbed lacrimal secretion and numbness of the cheek and gums. In 2007, Kikawada reported an endoscopic technique involving resection of the posterior nasal nerve near the sphenopalatine artery. With this technique, any intra-operative bleeding can be controlled under direct vision. In 2008, Ikeda et al. described submucosal reduction of the inferior turbinate and resection of the posterior nasal nerve. This resulted in significant improvements in nasal symptoms for patients with resistant chronic rhinitis (rhinorrhea). The posterior nasal nerve is a peripheral branch of the sphenopalatine ganglion. It enters the nasal cavity through a separate foramen, 4-5 mm below the sphenopalatine foramen, after bifurcation of the nerve into the lacrimal nerve. The posterior superior nasal nerves innervate the superior and middle turbinates, and the superior and middle meatus. Other parasympathetic nerve fibres of the nose branch off and joins the greater palatine nerve and enters the nasal cavity through the canaliculi in the perpendicular plate of the palatine bone as the posterior inferior nasal nerves. These nerves innervate the inferior turbinate and the inferior meatus.

NCT ID: NCT05870644 Completed - Allergic Rhinitis Clinical Trials

Acute Effects of Exercise at Different Temperatures in Allergic Rhinitis Patient

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study was to determine the effects of exercise at different temperatures on nasal blood flow and symptoms in allergic rhinitis patients.

NCT ID: NCT05779046 Completed - Allergic Rhinitis Clinical Trials

Acute Effect of High Intensity Interval Exercise in Patients With Allergic Rhinitis

Start date: September 10, 2022
Phase: N/A
Study type: Interventional

The purpose of this study was to determine the acute effect of high intensity interval exercise on respiratory function and rhinitis symptoms in allergic rhinitis patients.

NCT ID: NCT05753241 Completed - COVID-19 Clinical Trials

the Relationship Between Allergic Rhinitis and the Risk of Symptom in Patients With Mild COVID-19

Start date: November 10, 2022
Phase:
Study type: Observational [Patient Registry]

At present, most studies mainly focussed on severe patients, and there was no comparison of symptom differences between AR patients and healthy people with mild infection to evaluate the symptoms of AR patients during infection and to provide preventive treatment in advance. So this experiment was designed.

NCT ID: NCT05709977 Completed - Allergic Rhinitis Clinical Trials

Acupuncture for Nasal Congestion in Allergic Rhinitis

ANCAR
Start date: April 20, 2023
Phase: N/A
Study type: Interventional

Allergic rhinitis (AR) is a disorder that affects more than 500 million people worldwide. Nasal congestion is one of the most general and bothersome symptoms in rhinitis, which affects the quality of life (QOL). Current medications are undesirable due to their side-effects. Acupuncture for AR in general can be considered as safe and can be seen as a potential therapeutic intervention for nasal congestion. Evidence supported that acupuncture is clinically used for signs and symptoms of nose disorders, such as nasal congestion, with effectiveness, but whether acupuncture has immediate, post-treatment and long-term effects on nasal congestion in AR is not verified by strictly designed clinical study. The ANCAR trial uses a standard treatment protocol with a fixed set of acupuncture points - to be as scientific as possible from Western medical viewpoint - to open the nose and affect underlying energetic imbalance and immunity at the same time, to maintain its nose opening effect. This novel acupuncture treatment protocol can be seen as a solid and profound approach from which every AR patient may benefit.

NCT ID: NCT05707611 Completed - Allergic Rhinitis Clinical Trials

Acute Effects of Various Aerobic Exercise in Allergic Rhinitis.

Start date: August 1, 2020
Phase: N/A
Study type: Interventional

This study was to investigate the comparison among acute effects of various aerobic exercise on symptoms in allergic rhinitis patients.

NCT ID: NCT05693883 Completed - Allergic Rhinitis Clinical Trials

Pilates Training in Patients With Allergic Rhinitis

Start date: February 15, 2021
Phase: N/A
Study type: Interventional

The purpose of this study was to determine the effects of pilates training on symptoms in patients with allergic rhinitis.

NCT ID: NCT05692154 Completed - Clinical trials for Seasonal Allergic Rhinitis

A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis

FEXPRESAR
Start date: January 23, 2023
Phase: Phase 3
Study type: Interventional

This study is a proof-of-concept study to demonstrate if a daily dose of a 2-days pre-treatment of Fexofenadine 180mg is effective in alleviating the AR symptoms and to assess the additional benefit to the patient in terms of preventing Allergic Rhinitis (AR) symptoms. The total study duration per participant is expected at least 4 months, depending on the timing of the screening visit. 5 visits are planned, screening, confirmation inclusion challenge, randomization visit, challenge and end of study visit.

NCT ID: NCT05631197 Completed - Dental Caries Clinical Trials

Biomimetic Hydroxyapatite in Pediatric Patients With Asthma and/or Allergic Rhinitis

Start date: March 2, 2022
Phase: N/A
Study type: Interventional

The aim of the study is to compare the incidence of dental caries and the level of demineralization in pediatric patients with asthma and/or allergic rhinitis. Patients will conduct professional oral hygiene at the baseline. The following clinical indexes will be assessed: BEWE Index, Plaque Index, Bleeding Score, Schiff Air Index. Then, patients will be randomly divided into two groups: - Trial group: domiciliary use of Biorepair Total Protection Plus + desensitizing enamel-repair shock treatment twice a day - Control group: domiciliary use of Elmex Caries Protection twice a day The clinical indexes will be assessed again after 1 month (T1), after 3 (T2) and 6 months (T3).

NCT ID: NCT05590598 Completed - Clinical trials for Seasonal Allergic Rhinitis

Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.

Start date: February 13, 2023
Phase: Phase 3
Study type: Interventional

Prospective, multicenter, open, randomized, parallel, clinical study for assessment of comparative efficacy and safety of Azelastine +Mometasone Sandoz (main group) and Momat Rino Advance (control group) administered as a monotherapy to patients with seasonal allergic rhinitis (SAR).